San Diego, California, USA, September 1, 2026
Styx Biotechnologies Inc., a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, has announced a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected ADC programs toward first-in-human clinical studies. The collaboration is designed to provide a capital-efficient development pathway for Styx’s oncology pipeline while allowing the company to retain its broader global development rights. Under the agreement, Styx will receive an upfront payment and milestone-based payments linked to development progress, while ZoeNCure will provide development capital and leverage its specialized clinical infrastructure to support early-stage clinical studies. The companies said the financial details beyond these payments were not disclosed.
Strategic Collaboration Targets Clinical Advancement
The agreement is intended to help Styx move selected ADC candidates from preclinical development toward clinical validation without assuming the full financial burden normally associated with early clinical development. The collaboration will coordinate activities across preclinical development, chemistry, manufacturing and controls (CMC), regulatory planning and clinical execution, creating an integrated pathway toward first-in-human studies. Styx said the arrangement is expected to improve capital efficiency, potentially shorten development timelines and support the clinical de-risking of its lead programs while maintaining opportunities for future global development and partnering. ZoeNCure’s contribution of development funding and early-phase clinical infrastructure is expected to support the transition of selected programs into human testing.
Next-Generation ADC Pipeline Focuses on Solid Tumors
Styx is advancing a pipeline of novel antibody-drug conjugates for difficult-to-treat solid tumors, with programs spanning liver, gastric and rare cancers. The company’s approach combines tumor biology with differentiated antibody designs and dual-payload strategies intended to address important challenges such as tumor heterogeneity, therapeutic index and treatment resistance. ADCs are designed to use antibody targeting to deliver potent therapeutic payloads to cancer cells, making advances in antibody engineering, linker chemistry and payload selection important factors in improving treatment selectivity and efficacy. The Styx-ZoeNCure collaboration is intended to take selected assets closer to clinical testing, where their safety, tolerability, pharmacokinetics and preliminary biological activity can be evaluated in human participants.
Advertisement
CMC and Regulatory Activities Support First-in-Human Development
A key feature of the agreement is its coordinated focus on CMC and regulatory activities alongside clinical development. For complex ADCs, establishing appropriate manufacturing processes, analytical methods, product characterization and quality controls is an important component of preparing candidates for clinical evaluation. The companies said the collaboration will allow these activities to progress in parallel with preclinical and clinical planning. Styx expects this approach to create a more efficient route toward first-in-human clinical trials while continuing investment in its broader ADC portfolio. The company described the partnership as an important step in its strategy to advance promising oncology programs while preserving long-term value and flexibility for global development and strategic partnerships. The agreement also highlights the growing importance of strategic collaborations in ADC development, as biotechnology companies seek ways to advance increasingly complex oncology assets while managing the significant costs and operational requirements associated with clinical translation. For Styx, the partnership with ZoeNCure provides additional resources for early clinical development while retaining opportunities to pursue broader commercialization and development strategies. The companies believe the collaboration can establish a foundation for subsequent clinical development of selected next-generation ADC candidates and potentially accelerate their progression from laboratory-stage programs toward human trials.
Source: Styx Biotechnologies, ZoeNCure Therapeutics press release
